


Reducing Infection Rates



In a prospective randomized clinical trial, GI cancer surgery patients who received IMPACT® formula preoperatively had a 62% lower rate of infections vs. control (p<0.04).³

Study Objective: To evaluate the impact of preoperative oral administration of an immunonutrition (IM) drink (Oral IMPACT®^Δ) supplemented with arginine, omega-3 fatty acids and nucleotides on postoperative infections, immune response, and gut oxygenation/microperfusion in patients undergoing colorectal resection for cancer.

Synopsis:

- Intent to treat analysis (n=200) showed infection rates of:
 - 12% with preoperative IM for 5 days
 - 10% with perioperative IM for 5 days preop, 1.5L post-op
 - 32% with preoperative control (standard isonitrogenous/isocaloric drink [CD]) for 5 days
 - 30% with conventional treatment (no supplement)
- Among patients with infections, those in the treatment groups had significantly fewer days on antibiotics (preoperative IM vs. CD = 2.4 days, p<0.004).
- Treatment groups had significantly improved immune response (p<0.05), oxygenation (p<0.01), and microperfusion (p<0.02) compared with control/conventional groups.
- Length of stay (LOS) in the treatment groups was significantly shorter. Preoperative IM vs. CD yielded a 21% reduction in LOS (p<0.0005).

Outcome Variables	Peri-op (n = 50)	Pre-op (n = 50)	Control (n = 50)	Conventional (n = 50)
Death	1	0	0	1
Patients with infectious complications	5*	6†	16	15
Patients with noninfectious complications	5	4	3	4
Anastomotic leak	3	3	6	5
Antibiotic therapy** (d)	6.2 ± 1.9‡	6.5 ± 1.3§	8.9 ± 2.0	8.4 ± 1.8
Length of stay (d)	9.8 ± 3.1	9.5 ± 2.9¶	12.0 ± 4.5	12.2 ± 3.9

Data are number of patients or means ± SD.

*p < .02 vs control and conventional.

†p < .04 vs control and conventional.

‡p < .005 vs control and conventional.

§p < .004 vs control and conventional.

||p < .0001 vs control and conventional.

¶p < .0005 vs control and conventional.

**Only in patients who developed postoperative infections.

Adapted from Braga et al., Surg. 2002, Table II

Infection rate in control group: 32% (=16/50)
 Infection rate in pre-op group: 12% (=6/50)
 Reduction in infection rate: 62%

IMPROVING SURGICAL OUTCOMES WITH

IMPACT® Immunonutrition Formulas

Contains a unique blend of arginine, omega-3 fatty acids (EPA+DHA from fish oil), and nucleotides shown to reduce complications in major elective surgery patients³⁻¹¹

Consistent outcomes in over **80 publications** in major elective surgeries, including:
Upper GI, Lower GI, Cardiac, Head and Neck, Bladder Cancer, Gyn-Oncology, Hip



Nutrition Information

Serving Size	IMPACT ADVANCED RECOVERY® Drink		IMPACT® Formula	IMPACT® Peptide 1.5 Formula
	Per 178 mL carton	Per 534 mL (3 cartons)	Per 1000 mL	Per 1000 mL
Supplemental L-arginine (g)	4.2	12.6	12.5	18.7
EPA + DHA (g)	1.1	3.3	1.7	4.9
Nucleotides (g)	0.43	1.3	1.2	1.8
Calories (kcal)	200	600	1,000	1,500
Protein (g)	18 (35% of total kcal)	54 (35% of total kcal)	56 (22% of total kcal)	94 (25% of total kcal)

Ordering Information

PRODUCT	PRODUCT CODE	NDC FORMAT NUMBER	CASE UPC (GTIN)	PACKAGING
IMPACT® Unflavored	35810000	43900-0358-10	10043900358106	24-250 mL cartons/case
IMPACT® UltraPak® System	35810800	43900-0358-18	10043900358182	6-1000 mL bags/case
IMPACT ADVANCED RECOVERY® Vanilla	4390099291	43900-0992-90	00043900992914	15-178 mL cartons/case
IMPACT® Peptide 1.5 Unflavored	4390097400	43900-0973-99	10043900974009	24-250 mL cartons/case
IMPACT® Peptide 1.5 UltraPak® System	4390097371	43900-0973-70	10043900973712	6-1000 mL bags/case

NDC Formatted Numbers are not actual National Drug Codes (NDC). They are product codes adjusted according to standard industry practice to meet the format requirements of certain suppliers and payers. Nestlé HealthCare Nutrition submits product information including various product codes to the compendia including First Data Bank, RedBook and Medispan but cannot confirm that the NDC Formatted Numbers submitted have been published by the compendia.

References 1. Mauskopf JA et al. *WJSO* 2012;10:136. 2. Braga M et al. *Nutrition* 2005;21:1078-1086. 3. Braga M et al. *Surgery* 2002;132(5):805-814. 4. Braga M et al. *Arch Surg* 2002;137:174-180. 5. Drover JW et al. *J Am Coll Surg* 2011;212(3):385-399. 6. Ferreras N et al. *Clin Nutr* 2005;24:55-65. 7. Rowan NR et al. *Oral Onc* 2016;54:42-46. 8. Waitzberg DL et al. *World J Surg* 2006;30:1592-1604. 9. Chapman JS et al. *Gynecologic Oncology* 2015;137:523-528. 10. Tepaske R et al. *JPEN* 2007;31(3):173-180. 11. Bertrand J et al. *World J Urol* 2014;32:233-237.

USE UNDER MEDICAL SUPERVISION. NOT INDICATED WHEN IMMUNE SUPPRESSION IS DESIRED.

www.NestleHealthScience.us • 1-800-422-ASK2 (2752)

All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2016 Nestlé. All rights reserved.

IPCT-11994-0119

